Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.0900 |
| Open | 0.0900 |
| Bid | 0.0900 x N/A |
| Ask | 0.0950 x N/A |
| Day's Range | 0.0900 - 0.0950 |
| 52 Week Range | 0.0050 - 0.1600 |
| Volume | |
| Avg. Volume | 71,470 |
| Market Cap | 6.285M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D
- News Direct
Accelerating New Molecule Discovery: Rakovina Therapeutics AI Integration
Rakovina Therapeutics President and Chief Science Officer Mads Daugaard and Dr. Art Cherkasov from the Vancouver Prostate Centre and UBC joined Steve Darling from Proactive to unveil an exciting co...
- GlobeNewswire
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
Announces Capital Markets Advisory AgreementVANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, will be hosting an informational webinar on Wednesday, April 3, 2024. The Rakovina leadership team and members of the scientific team will host the co
